ILARISHCP.COM: Keyword Density Checker

Total words: 3622 | 2-word phrases: 936 | 3-word phrases: 1089 | 4-word phrases: 1146

PAGE INFO

Title	Try to keep the title under 60 characters (54 characters) ILARIS® (canakinumab) \| Health Care Professional Site
Description	Try to keep the meta description between 50 - 160 characters (157 characters) Discover information and resources to help HCPs identify autoinflammatory diseases like Gout Flares, SJIA, AOSD, and PFS. See full Prescribing & Safety Info.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	No H1 tag on the page (0 characters)

#	Keyword	Frequency	Density
1	the most common	8	0.73%
2	and pediatric patients	8	0.73%
3	have been reported	6	0.55%
4	indicated for the	6	0.55%
5	in patients with	6	0.55%
6	in clinical trials	6	0.55%
7	therapy with ilaris	6	0.55%
8	the risk of	6	0.55%
9	most common adverse	6	0.55%
10	reactions greater than	6	0.55%
11	reported with ilaris	5	0.46%
12	of serious infections	5	0.46%
13	upper respiratory tract	5	0.46%
14	associated periodic syndrome	5	0.46%
15	for the treatment	4	0.37%
16	and vertigo the	4	0.37%
17	treated with ilaris	4	0.37%
18	has not been	4	0.37%
19	adult and pediatric	4	0.37%
20	in adult and	4	0.37%
21	with ilaris in	4	0.37%
22	age and older	4	0.37%
23	of age and	4	0.37%
24	years of age	4	0.37%
25	vertigo the most	4	0.37%
26	the treatment of	4	0.37%
27	adult patients with	4	0.37%
28	patients with gout	4	0.37%
29	administration of ilaris	4	0.37%
30	to symptoms of	4	0.37%

#	Keyword	Frequency	Density
1	the most common adverse	6	0.52%
2	years of age and	4	0.35%
3	adult patients with gout	4	0.35%
4	vertigo the most common	4	0.35%
5	of age and older	4	0.35%
6	in adult and pediatric	4	0.35%
7	adult and pediatric patients	4	0.35%
8	with ilaris treatment in	4	0.35%
9	associated with ilaris treatment	4	0.35%
10	indicated for the treatment	4	0.35%
11	for the treatment of	4	0.35%
12	reactions greater than 10	4	0.35%
13	and vertigo the most	4	0.35%
14	associated with an increased	3	0.26%
15	ilaris has not been	3	0.26%
16	administering ilaris to patients	3	0.26%
17	with an increased risk	3	0.26%
18	the fire out of	3	0.26%
19	been associated with an	3	0.26%
20	has been associated with	3	0.26%
21	upper respiratory tract in	3	0.26%
22	take the fire out	3	0.26%
23	been reported with ilaris	3	0.26%
24	have been reported with	3	0.26%
25	because this may increase	2	0.17%
26	transported across the placenta	2	0.17%
27	mainly during the third	2	0.17%
28	this may increase the	2	0.17%
29	new tuberculosis tb and	2	0.17%
30	may increase the risk	2	0.17%
31	increase the risk of	2	0.17%
32	of new tuberculosis tb	2	0.17%
33	risk of new tuberculosis	2	0.17%
34	immunosuppression in the in	2	0.17%
35	in the in utero	2	0.17%
36	increased risk of new	2	0.17%
37	during the third trimester	2	0.17%
38	pregnancy and may cause	2	0.17%
39	the third trimester of	2	0.17%
40	third trimester of pregnancy	2	0.17%

#	URL	Whois	Check
1	https://www.novartis.us/sites/www.novartis.us/files/ilaris.pdf	Whois	novartis.us
2	https://www.ilaris.com/index.jsp	Whois	ilaris.com
3	https://www.pharma.us.novartis.com/utils/contact/hcp/emailh	Whois	novartis.com
4	https://www.novartis.us/sites/www.novartis.us/files/ilaris.pdf	Whois	novartis.us
5	https://www.novartis.us/sites/www.novartis.us/files/ilaris.pdf	Whois	novartis.us
6	https://medinfo.novartispharmaceuticals.com/	Whois	novartispharmaceuticals.com
7	https://www.novartis.us/about-us/contact-us	Whois	novartis.us
8	https://www.novartis.us/	Whois	novartis.us
9	https://www.novartis.us/terms-use	Whois	novartis.us
10	https://www.novartis.us/hcp-privacy-policy	Whois	novartis.us
11	https://www.novartis.us/	Whois	novartis.us